Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Short Communication



Can bevacizumab administered together with beta radiation in treatment of pterygium play a role in additive effect and/or treatment of the side effects?

Yasemin Benderli Cihan, Fatma Bagci.

Abstract
Pterygium is one of corneal-conjunctival pathologies that are frequently encountered by ophthalmologists. Its etiology, pathogenesis and treatment have been caused controversy for many years and remain as a problem, which is yet to be fully enlightened. The main treatment of pterygium is surgery. The most crucial postoperative problem is recurrence of the disease. Surgical methods have been sought for years to minimize recurrence with complementary treatment have been added to these methods including conjunctival autografting, bevacizumab and β-irradiation. No study was found to investigate additive use of bevacizumab and beta-radiation in postop or recurrent pterygium. Further phase 1 and phase 2 trials are needed to investigate the effectiveness of additive use of bevacizumab and beta-radiation in treatment of pterygium.

Key words: Bevacizumab, beta radiation, pterygium



Share this Article


Advertisement
American Journal of Physiology, Biochemistry and Pharmacology

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.